Cargando…
Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis
OBJECTIVE: Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical stud...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638898/ https://www.ncbi.nlm.nih.gov/pubmed/37954485 http://dx.doi.org/10.2147/DDDT.S428783 |
_version_ | 1785133695922864128 |
---|---|
author | Hu, Qichao Zeng, Jinhao Zhang, Xiaomei He, Tingting Zhang, Aozhe Li, Jianyu Wei, Shizhang Jing, Manyi Li, Haotian Wang, Xin Chang, Lei Ma, Xiao Zhao, Yanling |
author_facet | Hu, Qichao Zeng, Jinhao Zhang, Xiaomei He, Tingting Zhang, Aozhe Li, Jianyu Wei, Shizhang Jing, Manyi Li, Haotian Wang, Xin Chang, Lei Ma, Xiao Zhao, Yanling |
author_sort | Hu, Qichao |
collection | PubMed |
description | OBJECTIVE: Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical study was conducted. And metabolomics was used to explore the mechanism of WZYD for CNAG patients. METHODS: Twenty patients in total were recruited in this study (Nos. ChiCTR2200062296) and the protocol was approved by the Ethics Committee (Approval number: KY-2022-2-6-1) and complied with the Declaration of Helsinki. The formula granule of WZYD were assessed by UHPLC-QQQ-TOF to discern the main potential active compounds. The endoscopy evaluation and histopathological changes were detected as effective indicators. Serum samples from patients were used for metabolomics. Inflammatory factors in patients’ serum were determined by ELISA. Metabolomics revealed a series of differential metabolites and signaling pathways. RESULTS: WZYD was capable to prevent CNAG by ameliorating score of endoscopy evaluation including erosion, hemorrhage, as well as chronic inflammation and active chronic inflammation score after treatment were decreased. The results indicated that 10 core metabolic components were associated with the treatment of WZYD. Moreover, these metabolic components proved that pyrimidine metabolism and thiamine metabolism were critically responsible for CNAG. In addition, WZYD treatment effectively reduced serum levels of TNF-α, IL-10, and COX-2. CONCLUSION: Altogether, WZYD can effectively alleviate CNAG by inhibiting inflammation and regulating related metabolic processes, which might be the molecular mechanism of WZYD treatment of CNAG. More studies are warranted to be conducted in this area. TRIAL REGISTRATION: ChiCTR, ChiCTR2200062296. Registered 1 August 2022, https://www.chictr.org.cn/com/25/showprojen.aspx?proj=174027. |
format | Online Article Text |
id | pubmed-10638898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-106388982023-11-11 Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis Hu, Qichao Zeng, Jinhao Zhang, Xiaomei He, Tingting Zhang, Aozhe Li, Jianyu Wei, Shizhang Jing, Manyi Li, Haotian Wang, Xin Chang, Lei Ma, Xiao Zhao, Yanling Drug Des Devel Ther Original Research OBJECTIVE: Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical study was conducted. And metabolomics was used to explore the mechanism of WZYD for CNAG patients. METHODS: Twenty patients in total were recruited in this study (Nos. ChiCTR2200062296) and the protocol was approved by the Ethics Committee (Approval number: KY-2022-2-6-1) and complied with the Declaration of Helsinki. The formula granule of WZYD were assessed by UHPLC-QQQ-TOF to discern the main potential active compounds. The endoscopy evaluation and histopathological changes were detected as effective indicators. Serum samples from patients were used for metabolomics. Inflammatory factors in patients’ serum were determined by ELISA. Metabolomics revealed a series of differential metabolites and signaling pathways. RESULTS: WZYD was capable to prevent CNAG by ameliorating score of endoscopy evaluation including erosion, hemorrhage, as well as chronic inflammation and active chronic inflammation score after treatment were decreased. The results indicated that 10 core metabolic components were associated with the treatment of WZYD. Moreover, these metabolic components proved that pyrimidine metabolism and thiamine metabolism were critically responsible for CNAG. In addition, WZYD treatment effectively reduced serum levels of TNF-α, IL-10, and COX-2. CONCLUSION: Altogether, WZYD can effectively alleviate CNAG by inhibiting inflammation and regulating related metabolic processes, which might be the molecular mechanism of WZYD treatment of CNAG. More studies are warranted to be conducted in this area. TRIAL REGISTRATION: ChiCTR, ChiCTR2200062296. Registered 1 August 2022, https://www.chictr.org.cn/com/25/showprojen.aspx?proj=174027. Dove 2023-11-07 /pmc/articles/PMC10638898/ /pubmed/37954485 http://dx.doi.org/10.2147/DDDT.S428783 Text en © 2023 Hu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hu, Qichao Zeng, Jinhao Zhang, Xiaomei He, Tingting Zhang, Aozhe Li, Jianyu Wei, Shizhang Jing, Manyi Li, Haotian Wang, Xin Chang, Lei Ma, Xiao Zhao, Yanling Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis |
title | Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis |
title_full | Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis |
title_fullStr | Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis |
title_full_unstemmed | Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis |
title_short | Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis |
title_sort | metabolomics profiles reveal the efficacy of wuzhuyu decoction on patients with chronic non-atrophic gastritis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638898/ https://www.ncbi.nlm.nih.gov/pubmed/37954485 http://dx.doi.org/10.2147/DDDT.S428783 |
work_keys_str_mv | AT huqichao metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT zengjinhao metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT zhangxiaomei metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT hetingting metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT zhangaozhe metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT lijianyu metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT weishizhang metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT jingmanyi metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT lihaotian metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT wangxin metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT changlei metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT maxiao metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis AT zhaoyanling metabolomicsprofilesrevealtheefficacyofwuzhuyudecoctiononpatientswithchronicnonatrophicgastritis |